Contributors
-
TwentyTwentyTweets
-
Join 7,195 other subscribers
-
Recent Posts
Pages
Category Archives: Policy
#AI – Diagnosis on demand – and disappointment
Thursday evening’s Horizon, subtitled ‘The Computer will see you now’ is the latest in a lengthening line of programmes and books that purport to critique today’s medical zeitgeist: Artificial Intelligence in healthcare. It was entertaining. I understand. Who would have … Continue reading
Posted in Information, Policy, Technology
Tagged Ai, Babylon, Computer, digital health, Horizon, innovation, Kheiron
Leave a comment
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Prevention is better than cure.
The economic consequences of preventing illness are highly complex. Just comparing the costs of prevention with the direct treatment costs that should be avoided is far too simplistic. The true economic impact of preventative measures can often only be assessed … Continue reading
Posted in Alcohol, Business, Children, Elderly, Health Bill, Healthcare, Information, Jeremy Hunt, NHS, Obesity, Patient choice, Patients, Policy, Uncategorized
Tagged accidents, alcohol, Andrew Lansley, arthritis, cancer, cardiovasculsr, cause of dsath, choice, elderly, government, health, Health Bill, injury, Jeremy Hunt, longevity, mortality, National Health Service, NHS, Obesity, Patients, prevention, Public Health, respiratory, smoking, tobacco
Leave a comment
Guest Blogspot: The NHS Constitution- the turning point?
The Health and Social Care Act 2012 has always had my support. All my concerns were addressed in the final Act. The thrust of the Bill remained intact. However, like many other people I was dismayed by the strength of … Continue reading
Posted in Andrew Lansley, Department of Health, Health Bill, Health Team, Healthcare, Hospitals, Innovation, Jeremy Hunt, NHS, Patients, Policy
Tagged 2020health, Andrew Lansley, Constitution, Department of Health, Future Forum, Health and Social Care Act, Health Bill, National Health Service, NHS, NHS complaint, NHS Constitution, NHS Future Forum, patient, Patients, Public Health, traction
Leave a comment
Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.
David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading
Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care
Tagged 2020health, block-buster, competition, David Cameron, demand, Department of Health, drug pricing system, Drugs, elderly, GP, GPs, Health Bill, innovation, medicine, National Health Service, NHS, NICE, parallel exports, parallel imports, patient, Patients, pharmaceutical, Philosophy and Economics, Politics, PPE, PPRS, pricing, quality of life, R&D, reference price, Research, value-based, value-based pricing, VBP
Leave a comment
Guest Blogspot: Do private patients in the UK help or harm the NHS?
Private medicine like private education and first-class travel can stir up feelings of resentment between the “haves” and “have-nots”. A short blog like this one has no possibility of uniting stereotypical politicians from the left and right wings of politics. … Continue reading
Posted in Business, Department of Health, Drugs, Elderly, GPs, Health Bill, Health Team, Healthcare, Hospitals, Inequality, mental health, NHS, Nursing, Patient choice, Patients, Pharma, Policy, Private, Research
Tagged 2020health, choice, Consultant, Cosmetic Surgery, Dental, Department of Health, Drugs, elderly, Gamma Knife, General practitioner, government, GP, GPs, health, Health Bill, Medical Insurance, medicine, mental health, National Health Service, NHS, outcomes, patient, Patients, pharmaceutical, Prescription Charge, Private Hospital, Private Medicine, Private Patient, Research
Leave a comment
Guest Blogspot: Management Priorities in the NHS under the Health and Social Care Act
Basic economics relating to the pressures on the NHS led to the need for reform culminating in the Health and Social Care Act. The financial challenges faced by any healthcare system are strongly influenced by rising life expectancy without a … Continue reading
Posted in Demand Reduction, Elderly, Employment, Health Bill, Healthcare, NHS, Policy, Private, Work
Tagged 2020health, care of elderly, demographic pressure, Department of Health, elderly, future of nhs, government, health, Health Bill, healthy lifestyle, life expectancy, National Health Service, NHS, nhs protest, nhs values, Old age, outcomes, patient, Patients
2 Comments
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology
Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing
Leave a comment
Our leaders need to learn from the Lady of Downing Street
First published 30 March, 2012, on Mail Online There was once a lady who lived in Downing Street. She had married a wealthy man and worked incredibly hard, wanting to ensure that people were provided for at a time when … Continue reading
Posted in Policy
Leave a comment
2020health's Blog 
You must be logged in to post a comment.